Overview

This trial is active, not recruiting.

Condition metastatic breast cancer
Treatments trastuzumab, pertuzumab, paclitaxel, vinorelbine, t-dm1
Phase phase 2
Targets HER, HER2
Sponsor Swiss Group for Clinical Cancer Research
Start date July 2013
End date November 2017
Trial size 208 participants
Trial identifier NCT01835236, 2012-002556-17, SAKK 22/10, UNICANCER UC-0140/1207

Summary

In HER2-positive metastatic breast cancer, trastuzumab based treatment is the standard of care as long as there are no contraindications to trastuzumab. Frequently, trastuzumab is being combined with taxanes in the first-line setting. However, since therapy with trastuzumab is active even in the absence of chemotherapy in HER2-positive MBC, the optimal treatment strategy either in combination or in sequence with chemotherapy is still under debate. This randomized phase II trial is studying a new strategy for the treatment of metastatic breast cancer with HER2-positive. First-line treatment consists of trastuzumab and pertuzumab, a treatment without chemotherapy. In case of disease progression, chemotherapy with T-DM1 is then performed as second-line treatment. Third-line and further line therapies are performed according to the physician's discretion. If this new therapeutic strategy is as effective and better tolerated than the conventional strategy, this would mean a serious breakthrough in the treatment of HER2-positive metastatic breast cancer.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Active Comparator)
First line therapy: Trastuzumab, Pertuzumab Second line therapy: T-DM1
trastuzumab Herceptin
First administration (loading dose) 8 mg/kg i.v. infusion over 90 min. - then every 3 weeks until progression 6 mg/kg i.v. infusion over 30 to 90 min.
pertuzumab Perjeta
First administration (loading dose) 840 mg i.v. infusion over 60 min. - then every 3 weeks until progression 420 mg i.v. infusion over 30 to 60 min.
t-dm1 Trastuzumab emtansine
Every 3 weeks until unacceptable toxicity or progressive disease is observed 3.6 mg/kg i.v. infusion First dose: over 90 min (± 10 min.) Subsequent doses: over 30 min. (± 10 min.)
(Active Comparator)
First line therapy: Trastuzumab, Pertuzumab, Paclitaxel or Vinorelbine Second line therapy: T-DM1
trastuzumab Herceptin
First administration (loading dose) 8 mg/kg i.v. infusion over 90 min. - then every 3 weeks until progression 6 mg/kg i.v. infusion over 30 to 90 min.
pertuzumab Perjeta
First administration (loading dose) 840 mg i.v. infusion over 60 min. - then every 3 weeks until progression 420 mg i.v. infusion over 30 to 60 min.
paclitaxel Taxol
Day 1, 8 and 15; every 4 weeks for ≥4 months 90 mg/m2 i.v. infusion
vinorelbine Navelbine
First administration: Day 1 and 8 25 mg/m2 i.v. infusion then day 1 and 8, every 3 weeks for ≥4 months 30 mg/m2 i.v. infusion
t-dm1 Trastuzumab emtansine
Every 3 weeks until unacceptable toxicity or progressive disease is observed 3.6 mg/kg i.v. infusion First dose: over 90 min (± 10 min.) Subsequent doses: over 30 min. (± 10 min.)

Primary Outcomes

Measure
Overall survival (OS) - Analysis Population: ITT Population 1
time frame: 24 months

Secondary Outcomes

Measure
OS - Analysis Population: ITT Population 2
time frame: 24 months
Progression Free Survival (PFS) of first-line treatment ignoring first Central Nervous System (CNS) lesion
time frame: 10 / 16 months (PFS will be calculated sustained from randomization until documented PD (ignoring first CNS lesion) or death, whichever occurs first during first-line treatment )
PFS of second-line treatment
time frame: 8 months (PFS will be calculated sustained from registration of second line treatment until documented PD, PD CNS or death, whichever occurs first during second-line treatment)
PFS of second-line treatment ignoring first CNS lesion
time frame: 9 months (PFS will be calculated sustained from registration of second line treatment until documented PD (ignoring first CNS lesion) or death, whichever occurs first during second-line treatment)
Time to failure of strategy (TFS) of first- plus second-line treatment
time frame: 18 / 24 months (TFS will be calculated sustained from randomization until documented PD, PD CNS or death, whichever occurs first before starting third-line therapy )
Overall survival OS
time frame: OS will be calculated from randomization until death (estimated median: 32 months)
Objective response (OR) of first-line treatment (based on investigator assessment)
time frame: 10 / 16 months (OR is defined as the best status of response CR or PR up to first progression or start of a new treatment)
Disease control (DC) of first-line treatment (based on investigator assessment)
time frame: 6 months (DC is defined as CR, PR or SD for 6 months after randomization and no PD at 6 month after randomization)
OR of second-line treatment (based on investigator assessment)
time frame: 9 months (OR is defined as the best status of response CR or PR after registration for second-line treatment up to second progression or start of a new treatment)
DC of second-line treatment (based on investigator assessment)
time frame: 6 months (DC is defined as the response CR, PR or SD for 6 months after registration of second-line treatment)
Adverse events (AEs) according to the NCI CTCAE v4.0 of first-line treatment
time frame: Throughout first-line treatment (estimated up to 16 months)
AEs according to the NCI CTCAE v4.0 of second-line treatment
time frame: Throughout second-line treatment (estimated up to 9 months)
AEs grade ≥2 until first progression (ignoring first CNS lesion)
time frame: Throughout first-line treatment (estimated up to 16 months)
Quality of Life (QoL)
time frame: At baseline and every 12 weeks (three-monthly) until progression or up to a maximum of 24 months during 1st line therapy. Within 3 weeks prior to registration, after 12 and 24 weeks during 2nd line therapy.
PFS of third-line treatment
time frame: 4 months

Eligibility Criteria

Female participants at least 18 years old.

SELECTION OF PATIENTS (MOST IMPORTANT CRITERIA) Inclusion criteria for first-line therapy • Histologically confirmed breast cancer with distant metastases Note: 1. A biopsy from the primary tumor or a metastasis can be used for diagnosis. 2. Patients with non-measurable lesions are eligible. 3. Patients with inoperable, locally advanced breast cancer with lymph node metastases other than ipsilateral locoregional (axillary, infraclavicular, parasternal) or other distant metastases are eligible. 4. Patients with bone metastases with or without bone targeted therapy (bisphosphonates, denosumab) are eligible. 5. Patients with de-novo Stage IV disease are eligible. - HER2-positive tumor according to central pathology testing for HER2 Note: 1. A formalin-fixed paraffin-embedded (FFPE) biopsy from the primary tumor or a metastasis has to be used for HER2 status determination. If a biopsy is available from a metastasis, the HER2 testing should be performed using the metastasis. 2. Fine needle aspiration is not acceptable for HER 2 testing. • Women aged ≥18 years • WHO performance status 0 to 2 - Left Ventricular Ejection Fraction (LVEF) ≥50% as determined by either ECHO or MUGA - Adequate organ function, evidenced by the following laboratory results: Neutrophils >1.5x109/L, platelets >100x109/L, hemoglobin ≥90g/L, total bilirubin ≤1.5xULN (unless the patients has documented Gilbert's disease), AST ≤3xULN, ALT ≤3xULN, AP ≤2.5xULN (except in patients with bone metastases: AP ≤5xULN), creatinine ≤1.5xULN Exclusion criteria for first-line therapy • Prior chemotherapy for inoperable locally advanced or metastatic breast cancer Note: Prior neoadjuvant/adjuvant chemotherapy is allowed if doses for anthracyclines have not exceeded 720mg/m2 and 240mg/m2 for epirubicin and doxorubicin, respectively. - Re-exposure to paclitaxel is permitted, if the last dose of taxane was given at least 1 year before randomization. - Re-exposure to vinorelbine is permitted, if the last dose of vinorelbine was given at least 1 year before randomization. - Prior anti-HER2 treatment for metastatic or inoperable breast cancer Note: Prior neoadjuvant/adjuvant anti-HER2 treatment with trastuzumab and/or lapatinib is allowed. • More than one endocrine treatment line for metastatic or inoperable breast cancer exceeding a duration of 1 month Note: 1. Adjuvant endocrine treatment is not counted as one line. 2. Patients progressing on endocrine treatment: this specific endocrine treatment must have been stopped at least 2 weeks prior to randomization. • Prior treatment with pertuzumab and/or T-DM1 • Known leptomeningeal or CNS metastases Note: A brain MRI or CT scan is mandatory in case of clinical suspicion of CNS metastases. • Single bone metastasis treated with radiotherapy (if the bone metastasis is the only tumor lesion) Inclusion criteria for second-line therapy • At least one dose of trial therapy in the first-line treatment phase of this trial • • Proven disease progression on first-line therapy or radiotherapy of a bone metastasis Notes: First new parenchymal CNS metastases only do not count as progression requiring the initiation of second line trial treatment. Radiotherapy of a single area only for pain control is allowed and will not count as PD. • Adequate organ function, evidenced by the following laboratory results: Neutrophils >1.5x109/L, platelets >100x109/L, hemoglobin ≥90g/L, total bilirubin ≤1.5xULN (unless the patients has documented Gilbert's disease), AST ≤3xULN, AP ≤2.5xULN (except in patients with bone metastases: AP ≤5xULN), creatinine ≤1.5ULN • LVEF ≥50% as determined by either ECHO or MUGA • QoL questionnaire has been completed. Exclusion criteria for second-line therapy • Termination of first-line therapy with trastuzumab/pertuzumab due to unacceptable toxicity without objective evidence of disease progression • CNS metastases that are untreated, symptomatic, or require therapy to control symptoms, as well as a history of radiation, surgery, or other therapy, including steroids, to control symptoms from CNS metastases within 2 months (60 days) before registration • Peripheral neuropathy of CTCAE grade ≥3 - Interstitial lung disease (ILD) or pneumonitis grade ≥3 - Any other adverse event which has not recovered to CTCAE grade ≤1 (except alopecia)

Additional Information

Official title A Randomized Phase II Trial of Pertuzumab in Combination With Trastuzumab With or Without Chemotherapy, Both Followed by T-DM1 in Case of Progression, in Patients With HER2-positive Metastatic Breast Cancer
Description OBJECTIVES: Primary -To evaluate the efficacy in terms of overall survival (OS) at 24 months of a chemotherapy-free dual HER2-inhibition with trastuzumab and pertuzumab (first-line) followed by T-DM1 (second-line) and of a chemotherapy-containing dual HER2-inhibition with trastuzumab and pertuzumab (first-line) followed by T-DM1 (second-line) in patients with HER2-positive metastatic breast cancer. Secondary - To evaluate other efficacy parameter - To evaluate the safety and tolerability profile of the two treatment strategies - To evaluate the Quality of Life (QoL) - To learn how patients are treated after trial treatment OUTLINE: This is a multicenter study. Patients are stratified according to hormone receptor status (positive vs negative), prior trastuzumab (never or >12 months vs ≤12 months after last infusion), visceral metastases (present vs absent) and site. Patients are randomized to 1 of 2 treatment arms.
Trial information was received from ClinicalTrials.gov and was last updated in June 2016.
Information provided to ClinicalTrials.gov by Swiss Group for Clinical Cancer Research.